China Pharma Holding's quarterly market cap
increased
from Sep. 2025 ($9.79 Mil) to Dec. 2025 ($18.78 Mil) and
increased
from Dec. 2025 ($18.78 Mil) to Mar. 2026 ($24.72 Mil).
China Pharma Holding's annual market cap
increased
from Dec. 2023 ($6.43 Mil) to Dec. 2024 ($7.58 Mil) and
increased
from Dec. 2024 ($7.58 Mil) to Dec. 2025 ($18.78 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. China Pharma Holding's Enterprise Value for Today is $26.79 Mil.
China Pharma Holding (AMEX:CPHI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
China Pharma Holding Market Cap Related Terms
China Pharma Holding Market Cap Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Market Cap distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
China Pharma Holding's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding (CPHI) has a Market Cap of $23.10 Mil as of Jul. 10, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on China Pharma Holding and its competitors. According to the industry distribution chart, China Pharma Holding ranks #775 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 75.7%.
Is China Pharma Holding's Market Cap too high?
China Pharma Holding's current Market Cap is $23.10 Mil. The Drug Manufacturers industry median Market Cap is 214.09. China Pharma Holding's value of $23.10 Mil is 89.2% below this industry median. Based on the distribution chart, China Pharma Holding ranks #775 out of 1024 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Pharma Holding has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Market Cap compare to TXMD and RMTI?
According to the Drug Manufacturers industry distribution chart, China Pharma Holding ranks #775 out of 1024 companies for Market Cap. This places China Pharma Holding in the lower half of its industry. The industry median Market Cap is 214.09. China Pharma Holding's value of $23.10 Mil is 89.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 214.09, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Pharma Holding's current Market Cap of $23.10 Mil is 89.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on China Pharma Holding and its competitors. For the Drug Manufacturers industry, the median Market Cap is 214.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Pharma Holding's current Market Cap is $23.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
Based on GuruFocus' analysis, China Pharma Holding (CPHI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.57 — trading 137.5% above its estimated fair value. The current Market Cap is $23.10 Mil and 89.2% below the Drug Manufacturers industry median of 214.09. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For China Pharma Holding (CPHI), the current Market Cap is $23.10 Mil as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (CPHI) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of $0.57 is trading 137.5% above its estimated GF Value™ of $0.24.
GuruFocus considers China Pharma Holding to be Significantly Overvalued.
Key valuation signals for CPHI:
Market Cap: $23.10 Mil
GF Value™: $0.24 vs. price of $0.57 (137.5% above fair value)
Industry Position: 89.2% below the Drug Manufacturers median (#775 of 1024)
No single metric tells the full story. See the CPHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score
Get the complete analysis for CPHI
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHI has been successfully added to your 
